CLINICAL TRIAL: PHI-59: PHASE I AND PHARMAKOKINETIC STUDY OF VORINOSTAT

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的目的是找出在出现无法控制的副作用之前，对晚期癌症和不同程度肝功能的受试者可以给予研究药物涡流抑制的最高剂量。这项研究的其他目的将是检查当给具有不同程度肝功能的受试者服用该药物时会发生什么副作用，在接受药物后的特定时间血液中有多少涡流调节剂，以及涡流调节剂是否对治疗各种类型的晚期癌症有效。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to find out the highest possible dose of the investigational drug vorinostat that can be given to subjects with advanced cancer and different degrees of liver function before unmanageable side effects are seen. Other purposes of this research study will be to examine what side effects occur when the drug is given to subjects with different degrees of liver function, how much vorinostat is in the blood at specific times after it is received, and whether or not vorinostat is effective in treating various types of advanced cancer.